ICYMI, this week we had stories about blastic plasmacytoid dendritic cell neoplasm, epidermolysis bullosa, an interview with Seth Matarasso, MD, and more.
Click here to answer this week's poll.
Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss pathogenesis of plaque psoriasis and new emerging targets.
Drs Mark G. Lebwohl and Alice B. Gottlieb discuss how to select treatment for plaque psoriasis based on mechanism of action.
Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are trending for the month of October.
MD is a type of delusional parasitosis where patients report that their skin contains parasites, toxins, fibers, or other foreign material.
Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, review the recent trajectory of the atopic dermatitis therapeutic spectrum, notably how several newer approvals have changed how clinicians approach treatment.
Thought leaders discuss why JAK inhibitors are well suited for the management of itch and inflammation in the treatment of moderate to severe atopic dermatitis.
Patient-reported outcome measures ensure patients' experiences are documented during new treatments.
Erythropoietic protoporphyria (EPP) is a life-long and debilitating disorder resulting from defects in the enzymes in heme synthesis. Patients with the disease are cast indoors due to extreme photosensitivity.
Epidermolysis bullosa is a broad term used to identify a group of genetic disorders that result in skin blistering and fragility.
Blastic plasmacytoid dendritis cell neoplasm is a rare and aggressive form of cancer that usually makes its appearance in the form of red to violet papules and plaques.
The Centers for Medicare and Medicaid Services is looking to change the way cellular and/or tissue-based products for skin wounds are coded and paid for in physician offices.
Honey has long been known to have remarkable antimicrobial and tissue-regenerative properties.
Will Kirby, DO, FAOCD, talks with Dustin Portela, DO, FAAD, about TikTok, what being a KOL really means, and the biggest aesthetic myth in the industry right now.
Recent studies show patients are experiencing adverse effects of stopping corticosteroid treatment.
Nonsteroidal topical agents and TYK2 inhibitors may join an already full armamentarium.
Seth Matarasso, MD, discusses upcoming innovations in neuromodulators and additional highlights from his presentation at ASDS in Denver, Colorado.
Christopher Bunick, MD, PhD, shares his thoughts on the latest report of concerning levels of benzene, a human carcinogen, found in dry shampoos recalled last month.